SCHEMBL2840488

SCHEMBL2840488

CNC(=O)c1ccc(Oc2ccc3nc(NCC4CCCCC4)sc3c2)cn1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CSF1R P07333 6/20 0.56
PDGFRB P09619 1/20 0.56
KIT P10721 1/20 0.56
PDGFRA P16234 1/20 0.56
FLT3 P36888 1/20 0.56
RAF1 P04049 5/20 0.51
BRAF P15056 5/20 0.51
MAPT P10636 3/20 0.47
NPC1 O15118 3/20 0.47
RAB9A P51151 3/20 0.47
PKM P14618 1/20 0.47
HRH3 Q9Y5N1 1/20 0.46
KCNH2 Q12809 1/20 0.46
KDM4E B2RXH2 1/20 0.43
TP53 P04637 1/20 0.43
GLA P06280 1/20 0.43
PIP5K1C O60331 1/20 0.43
PIK3CA P42336 1/20 0.43
PI4KA P42356 1/20 0.43
PI4KB Q9UBF8 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2676259 0.89 CSF1R (0.70) CSF1RPDGFRBKITPDGFRAFLT3
SCHEMBL2677847 0.89 CSF1R (0.70) CSF1RPDGFRBKITPDGFRAFLT3
SCHEMBL2845153 0.86 CSF1R (0.50) CSF1RPDGFRBKITPDGFRAFLT3
SCHEMBL2676217 0.84 CSF1R (0.68) CSF1RPDGFRBKITPDGFRAFLT3
SCHEMBL2846759 0.83 CSF1R (0.55) CSF1RPDGFRBKITPDGFRAFLT3
SCHEMBL2846761 0.83 CSF1R (0.55) CSF1RPDGFRBKITPDGFRAFLT3
SCHEMBL2842436 0.83 CSF1R (0.49) CSF1RPDGFRBKITPDGFRAFLT3
SCHEMBL14025976 0.83 RAF1 (0.55) CSF1RPDGFRBKITPDGFRAFLT3
SCHEMBL2848159 0.82 CSF1R (0.81) CSF1RPDGFRBKITPDGFRAFLT3
SCHEMBL14024731 0.82 CSF1R (0.48) CSF1RPDGFRBKITPDGFRAFLT3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8293769-B2 CSF-1R inhibitors, compositions, and methods of use NOVARTIS AG (CH) 2012-10-23 US claimed
US-20100130490-A1 CSF-1R INHIBITORS,COMPOSITIONS, AND METHODS OF USE NOVARTIS AG (CH) 2010-05-27 US claimed
US-8293769-B2 CSF-1R inhibitors, compositions, and methods of use NOVARTIS AG (CH) 2012-10-23 US disclosed
US-8293769-B2 CSF-1R inhibitors, compositions, and methods of use NOVARTIS AG (CH) 2012-10-23 US disclosed
US-8293769-B2 CSF-1R inhibitors, compositions, and methods of use NOVARTIS AG (CH) 2012-10-23 US disclosed
US-20100130490-A1 CSF-1R INHIBITORS,COMPOSITIONS, AND METHODS OF USE NOVARTIS AG (CH) 2010-05-27 US disclosed
US-20100130490-A1 CSF-1R INHIBITORS,COMPOSITIONS, AND METHODS OF USE NOVARTIS AG (CH) 2010-05-27 US disclosed
US-20100130490-A1 CSF-1R INHIBITORS,COMPOSITIONS, AND METHODS OF USE NOVARTIS AG (CH) 2010-05-27 US disclosed
WO-2008144062-A1 CSF-1R INHIBITORS, COMPOSITIONS, AND METHODS OF USE NOVARTIS AG (CH) 2008-11-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100130490-A1 CSF-1R INHIBITORS,COMPOSITIONS, AND METHODS OF USE CSF1R, CSF3R, FLT3 CSF1R 1/4885PDGFRB 119/4885KIT 129/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.